

EGIR-RISC - Relationship between insulin sensitivity and cardiovascular disease

Head :Balkau Beverley
Ferrannini Ele

Last update : 09/05/2017 | Version : 2 | ID : 3301

General

Identification

Detailed name	Relationship between insulin sensitivity and cardiovascular disease
Sign or acronym	EGIR-RISC

General Aspects

Medical area	Endocrinology and metabolism
Health determinants	Addictions Social and psychosocial factors

Scientific investigator(s) (Contact)

Name of the director	Balkau
Surname	Beverley
Phone	0145595161
Email	beverley.balkau@inserm.fr
Organization	Inserm

Name of the director	Ferrannini
Surname	Ele

Collaborations

Funding

Funding status	Mixed
Details	Financement européen public, AstraZeneca, Merck

Governance of the database

Sponsor(s) or organisation(s)	Centre de Recherche en Nutrition Humaine de Lyon
-------------------------------	--------------------------------------------------

responsible (CRNHL)

Organisation status Public

Additional contact

Main features

Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is carried out as part of an interventional study No

Database objective

Main objective Main objective: study of insulin resistance and atherosclerosis, determinants of insulin resistance, its evolution on 9 years and consequences, diabetes, cardiovascular diseases and premature death.
Secondary objectives:
1. The evaluation of insulin resistance and its association with cardiovascular diseases
2. Identification of genetic and environmental factors linked to insulin resistance
3. The proposition of a model to identify insulin resistance

Inclusion criteria

- Aged between 30 and 60 years
- Good general health condition
- No symptoms of cardiovascular diseases
- blood pressure inferior to 170/90 mm Hg
- Total cholesterol inferior to 7,8 mmol/l
- Triglycerides levels inferior to 4,6 mmol/l
- Plasma glucose level (on an empty stomach and 2 hours after an oral glucose control) inferior to 7,0/11,1 mmol/l
- No treatment related to diabetes, hypertension or lipid disorders

Population type

Age Adulthood (25 to 44 years)
Adulthood (45 to 64 years)

Population covered	Sick population
Gender	Male Woman
Geography area	International
Detail of the geography area	Austria, Denmark, Finland, France, Germany, Greece, Netherlands, Ireland, Italy, Sweden, Spain, Switzerland, United Kingdom, Serbia and Montenegro

Data collection

Dates

Date of first collection (YYYY or MM/YYYY) 2002

Date of last collection (YYYY or MM/YYYY) 2007

Size of the database

Size of the database (number of individuals) [1000-10 000[individuals

Details of the number of individuals 1500

Data

Database activity Data collection completed

Type of data collected
Clinical data
Declarative data
Paraclinical data
Biological data

Clinical data (detail) Medical registration

Declarative data (detail) Phone interview

Paraclinical data (detail) Imaging at inclusion and at 3 years : carotid artery scan, Doppler of arm arteries, full body scan in 2 centers (about 150 subjects)

Biological data (detail) Plasma, serum, leukocyte layer, DNA

Presence of a biobank Yes

Contents of biobank Serum

Plasma
Fluids (saliva, urine, amniotic fluid, ?)
DNA

Details of biobank content At inclusion and at 3 years : blood (lipid profile, genetic characteristics analysis), urine

Health parameters studied Health event/morbidity
Health event/mortality

Procedures

Data collection method Interview questionnaire : (1) Life habits, family history (2) occurrence of diseases (3) Lifestyle (personal and family history, tobacco, alcohol, peripheral arterial disease, angina) (4) clinical signs or symptoms, diabetes or weight variation since the examinations (5) Clinical signs or symptoms of cardiovascular diseases, diabetes or weight variation since the examinations, sleep and depression. Clinical examination : (6) Anthropometric measures, blood pressure, ECB, "body-fat" measure by biometrical impedance analysis, hyperinsulinemic-euglycemic clamp, glucose tolerance test, glucose test IV, quantity and quality evaluation of physical activity (7) Anthropometric measures, blood pressure, ECB, "body-fat" measure by biometrical impedance analysis, glucose tolerance test, glucose test IV

Participant monitoring Yes

Details on monitoring of participants Follow-up questionnaire

Links to administrative sources No

Promotion and access

Promotion

Link to the document http://www.hal.inserm.fr/RISC_STUDY

Description List of publications in HAL

Link to the document [http://www.ncbi.nlm.nih.gov/pubmed/?term=%28Balkau\[Author\]%29+AND+%28Risc+OR+%22Risk+study%22%29+OR+20660046\[uid\]](http://www.ncbi.nlm.nih.gov/pubmed/?term=%28Balkau[Author]%29+AND+%28Risc+OR+%22Risk+study%22%29+OR+20660046[uid])

Description List of publications in Pubmed

Access

Terms of data access (charter for data provision, format of data, availability delay)	For data access, please submit a written request to the "project management board". Diffusion : oral communications during congresses, published articles, press releases, diffusion to general practitioners and diabetologists, newspapers
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only